Y-Mabs Therapeutics Inc (NASDAQ: YMAB) established initial surge of 10.31% at $11.88, before settling in for the price of $10.77 at the close. Taking a more long-term approach, YMAB posted a 52-week range of $5.31-$20.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 37.03%. Meanwhile, its Annual Earning per share during the time was 20.06%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -28.44%. This publicly-traded company’s shares outstanding now amounts to $43.67 million, simultaneously with a float of $37.18 million. The organization now has a market capitalization sitting at $532.10 million. At the time of writing, stock’s 50-day Moving Average stood at $13.54, while the 200-day Moving Average is $13.69.
Y-Mabs Therapeutics Inc (YMAB) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Y-Mabs Therapeutics Inc industry. Y-Mabs Therapeutics Inc’s current insider ownership accounts for 16.99%, in contrast to 60.15% institutional ownership. According to the most recent insider trade that took place on Sep 13 ’24, this organization’s CHIEF BUSINESS OFFICER sold 65,000 shares at the rate of 13.47, making the entire transaction reach 875,550 in total value, affecting insider ownership by 97,681. Preceding that transaction, on Sep 16 ’24, Company’s CHIEF BUSINESS OFFICER sold 30,000 for 12.97, making the whole transaction’s value amount to 389,100. This particular insider is now the holder of 67,681 in total.
Y-Mabs Therapeutics Inc (YMAB) Earnings and Revenue Records
Y-Mabs Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -28.44% and is forecasted to reach -0.57 in the upcoming year.
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Trading Performance Indicators
Let’s observe the current performance indicators for Y-Mabs Therapeutics Inc (YMAB). It’s Quick Ratio in the last reported quarter now stands at 3.54. The Stock has managed to achieve an average true range (ATR) of 0.91. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 6.29.
In the same vein, YMAB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.54, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.57 at the market close of one year from today.
Technical Analysis of Y-Mabs Therapeutics Inc (YMAB)
Now, what If we examine the latest scores posted by [Y-Mabs Therapeutics Inc, YMAB]. During the last 5-days, its volume was lower the volume of 0.33 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 47.70% While, its Average True Range was 0.93.
Raw Stochastic average of Y-Mabs Therapeutics Inc (YMAB) in the period of the previous 100 days is set at 45.06%, which indicates a major rise in contrast to 34.79% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 88.76% that was higher than 67.80% volatility it exhibited in the past 100-days period.
